174 related articles for article (PubMed ID: 16929084)
1. Establishment of reference values for endocrine tests--part V: acromegaly.
Endert E; van Rooden M; Fliers E; Prummel MF; Wiersinga WM
Neth J Med; 2006; 64(7):230-5. PubMed ID: 16929084
[TBL] [Abstract][Full Text] [Related]
2. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.
Elias PC; Lugao HB; Pereira MC; Machado HR; Castro Md; Moreira AC
Horm Metab Res; 2010 Jan; 42(1):50-5. PubMed ID: 19798623
[TBL] [Abstract][Full Text] [Related]
3. Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system.
Minuto F; Resmini E; Boschetti M; Arvigo M; Sormani MP; Giusti M; Ferone D; Barreca A
Clin Endocrinol (Oxf); 2004 Jul; 61(1):138-44. PubMed ID: 15212656
[TBL] [Abstract][Full Text] [Related]
4. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.
Colao A; Pivonello R; Cavallo LM; Gaccione M; Auriemma RS; Esposito F; Cappabianca P; Lombardi G
Clin Endocrinol (Oxf); 2006 Aug; 65(2):250-6. PubMed ID: 16886969
[TBL] [Abstract][Full Text] [Related]
5. Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice.
Pokrajac A; Wark G; Ellis AR; Wear J; Wieringa GE; Trainer PJ
Clin Endocrinol (Oxf); 2007 Jul; 67(1):65-70. PubMed ID: 17437512
[TBL] [Abstract][Full Text] [Related]
6. Biochemical evidence in favor of revising Cortina criteria.
Webb SM; Sucunza N; Barahona MJ
J Endocrinol Invest; 2005; 28(11 Suppl International):84-6. PubMed ID: 16625854
[TBL] [Abstract][Full Text] [Related]
7. Dynamic tests and basal values for defining active acromegaly.
Tzanela M
Neuroendocrinology; 2006; 83(3-4):200-4. PubMed ID: 17047383
[TBL] [Abstract][Full Text] [Related]
8. GH and mortality in acromegaly.
Sheppard MC
J Endocrinol Invest; 2005; 28(11 Suppl International):75-7. PubMed ID: 16625851
[TBL] [Abstract][Full Text] [Related]
9. Biochemical evidence supporting the Cortina criteria.
von Werder K
J Endocrinol Invest; 2005; 28(11 Suppl International):81-3. PubMed ID: 16625853
[TBL] [Abstract][Full Text] [Related]
10. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
Bastemir M; Akin F; Yaylali GF
Neuroendocrinology; 2007; 86(2):119-23. PubMed ID: 17671378
[TBL] [Abstract][Full Text] [Related]
11. Use of the oral glucose tolerance test to define remission in acromegaly.
Vierhapper H; Heinze G; Gessl A; Exner M; Bieglmayr C
Metabolism; 2003 Feb; 52(2):181-5. PubMed ID: 12601629
[TBL] [Abstract][Full Text] [Related]
12. Hormonal diagnosis of GH hypersecretory states.
Grottoli S; Gasco V; Ragazzoni F; Ghigo E
J Endocrinol Invest; 2003; 26(10 Suppl):27-35. PubMed ID: 15497657
[TBL] [Abstract][Full Text] [Related]
13. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly.
Biermasz NR; Pereira AM; Smit JW; Romijn JA; Roelfsema F
Growth Horm IGF Res; 2005 Jun; 15(3):200-6. PubMed ID: 15935982
[TBL] [Abstract][Full Text] [Related]
14. Serum IGF-I measured by four different immunoassays in patients with adult GH deficiency or acromegaly and in a control population.
Granada ML; Ulied A; Casanueva FF; Pico A; Lucas T; Torres E; Sanmartí A
Clin Endocrinol (Oxf); 2008 Jun; 68(6):942-50. PubMed ID: 17980002
[TBL] [Abstract][Full Text] [Related]
15. Establishment of reference values for endocrine tests. Part IV: Adrenal insufficiency.
Endert E; Ouwehand A; Fliers E; Prummel MF; Wiersinga WM
Neth J Med; 2005 Dec; 63(11):435-43. PubMed ID: 16397312
[TBL] [Abstract][Full Text] [Related]
16. Normal reference range of serum insulin-like growth factor (IGF)-I in healthy Thai adults.
Plengpanich W; Mangkala J; Buranasukajorn P; Boonruang K; Sunthornyothin S; Suwanwalaikorn S; Khovidhunkit W; Sridama V; Snabboon T
J Med Assoc Thai; 2008 Nov; 91(11):1681-4. PubMed ID: 19127789
[TBL] [Abstract][Full Text] [Related]
17. Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly.
Sherlock M; Aragon Alonso A; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
Clin Endocrinol (Oxf); 2009 Jul; 71(1):74-81. PubMed ID: 19178529
[TBL] [Abstract][Full Text] [Related]
18. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.
Carmichael JD; Bonert VS; Mirocha JM; Melmed S
J Clin Endocrinol Metab; 2009 Feb; 94(2):523-7. PubMed ID: 19033371
[TBL] [Abstract][Full Text] [Related]
19. Current diagnostic guidelines for biochemical diagnosis of acromegaly.
Ferone D; Resmini E; Bocca L; Giusti M; Barreca A; Minuto F
Minerva Endocrinol; 2004 Dec; 29(4):207-23. PubMed ID: 15765030
[TBL] [Abstract][Full Text] [Related]
20. Biochemical markers of acromegaly: GH vs. IGF-I.
Barkan AL
Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S97-100. PubMed ID: 15135787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
